Fierce Biotech November 29, 2022
While other biotechs are culling staff and programs to stay afloat, BigHat Biosciences has remained dry under its ever-expanding umbrella, announcing a multiprotein deal with Merck & Co. while growing its team 30% since the summer.
In a short amount of time, BigHat execs have realized there is a wide landscape of opportunities available to them, CEO and co-founder Mark DePristo, Ph.D., told Fierce Biotech in an interview.
“We’re trying to cherry-pick the right ones to pursue,” DePristo explained, adding that the Merck pact is one of the few deep collaborations the biotech has in mind.
Under the terms of the agreement announced this morning, Merck will use BigHat’s AI-enabled platform to optimize proteins for up to...
Today's Sponsors
Today's Sponsor